Fariba Sadeghi Fazel - Health Management Department, Quality Assurance Deputy, Razi Vaccine & Serum Research Institute, Karaj, Iran
Mahnaz Haddadi - Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
Alireza Khoshnevisan - Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
Samad Muhammadnejad - Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran
Ahad Muhammadnejad - Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
Zohreh Mazaheri - Anatomy Department, School of Medicine, Tarbiat Modares University, Tehran, Iran
Motahareh Arjomandnejad - Omid Institute for Advance Biomodels, Incubation Center for Medical Devices, Tehran University of Medical Sciences, Tehran, Iran
Reza Shirkoohi - Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
Mohammad-Ali Oghabian - Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran
Narjes Sherkat-Khameneh - Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran
Saeid Amanpour - Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
Monireh Kazemimanesh - Virology Department, Pasteur Institute of Iran, Tehran, Iran

Objective(s):P In vitro chemosensitivity and resistance assays (CSRAs) are a promising tool for personalized treatment of glioblastoma multiform (GBM). These assays require a minimum of ۱ to ۲ g of tumor specimen for testing, but this amount is not always accessible. We aimed to assess the feasibility and validity of utilizing stereotactic biopsies of GBM in CSRAs. Materials and Methods: Single cell suspension was prepared from ۱ g weight explants of the established xenograft tumor of GBM. Also, primary culture was carried out on ۳۵ mg weight specimens, as a surrogate for stereotactic biopsies. Then, chemoresponse profile of cells obtained by direct cell disaggregation and primary culture was determined using temozolomide and carmustine by clonogenic assay[AGA۱] . Results: There was no statistically significant difference in the cytotoxicity of temozolomide and carmustine between cells obtained from both methods. Conclusion: This work supports the feasibility of using stereotactic biopsies of GBM in CSRAs.

Glioblastomamultiform, In vitro chemosensitivity and resistance assay, Personalized Medicine, Primary, explant technique, Stereotactic biopsy